Objective: We previously developed normative data for a French version of the Hayling Sentence Completion Test (f-HSCT) for adults and elderly people. The present study aimed to evaluate the clinical utility of the f-HSCT norms in two clinical populations in which inhibition dysfunction has been largely documented, i.e., Parkinson's disease (PD) and schizophrenia. Method: Eighty-five non-demented patients with idiopathic PD and 64 out-patients with schizophrenia completed the automatic and inhibition conditions of the f-HSCT. Time latencies and errors raw data of each patient were compared to the norms previously developed by the authors. Results: In the automatic condition, errors were rare in both clinical groups and time latencies on this condition felt within the normative data range. Compared with the standardized norms, 46% of patients with PD and 61% of patients with schizophrenia had a deviant performance (i.e., borderline or deficit) for the inhibition error score. The proportion of patients with a deviant performance on the inhibition response time score was similar in both clinical samples (respectively, 25% and 23%). Finally, slightly more than half of patients with PD and more than two-thirds of patients with schizophrenia had a deviant performance on at least one of the f-HSCT inhibition measures. Conclusions: Our results suggest that the f-HSCT has a strong potential for characterizing inhibition of prepotent responses in PD and schizophrenia. Furthermore, it requires only a short administration time so it may be ideal to detect response inhibition in clinical populations with cognitive fatigue.
Introduction
The Hayling Sentence Completion Test (HSCT) is one of the most widely used instruments to measure a main executive function: the inhibition of prepotent responses (Diamond, 2013) . In research setting, between-group comparisons have largely documented a decrease in HSCT performances in individuals with a large variety of clinical conditions when compared to matched-healthy controls. These conditions include neurodegenerative disorders such as Alzheimer (Bayard, Jacus, Raffard, & Gély-Nargeot, 2014; Belleville, Rouleau, & Van der Linden, 2006) or Parkinson diseases (PD) (Obeso et al., 2011) , acquired brain injury (Dymowski, Owens, Ponsford, & Willmott, 2015; Robinson et al., 2015) , mental disorders such as schizophrenia (Fond et al., 2013; Martin, Mowry, Reutens, & Robinson, 2015) or neurodevelopmental conditions (Zimmerman, Ownsworth, O'Donovan, Roberts, & Gullo, 2016) .
In both research and clinical contexts, using normative data developed from healthy individuals to assess groups of patients may allow to identify the presence or absence of specific cognitive deficits. This is also a relevant issue in terms of indexing patient's evolution across time, which is a central concern when assessing the effectiveness of rehabilitation or of the cognitive profile evolution in both neurodegenerative and neurodevelopmental disorders. In other words, examination of individual profiles established from norms may shed a light on the way a test should be used in clinical practice. As pointed out by Belleville and coworkers (2006) , tests with a heterogeneous performance have strong clinical utility as qualifiers of differential impairment and potential markers for patient subtyping, and for the development of differential modes of intervention. In turns, clinical tools with highly homogenous impairment in a defined clinical population are likely to be powerful diagnostic markers of one specific cognitive alteration or another.
HSCT normative data exist for Canadian (Bielak, Mansueti, Strauss, & Dixon, 2006) , British (Burgess & Shallice, 1997) , and Spanish healthy populations (Pérez-Pérez et al., 2016) . We recently established HSCT normative data, adjusted for the linguistic and cultural realities of the French population (Bayard et al., accepted) . Overall and in spite of this background, to our knowledge, the clinical utility of HSCT has not been studied. This clinical aspect is nevertheless of fundamental interest for an appropriate interpretation of cognitive performances as a critical component of functional status in individuals with neuropsychological disturbances. According to this context, the general aim of the present work was to explore the clinical utility of our recent French's HSCT norms (Bayard et al., accepted) in two clinical populations with well-documented inhibitory control impairments that are schizophrenia and PD.
By applying f-HSCT normative data previously developed by authors, the objectives of the current study are threefold: (1) to assess the degree to which non-demented patients with PD and out-patients with schizophrenia in a stable phase of their illness are impaired on the f-HSCT indices, (2) to establish the sensitivity to the task at individual level in these two clinical populations, and (3) to determine the affect of clinical variables of the diseases on f-HSCT performance.
Method

Participants
Patients with Parkinson's disease. Eighty-five non-demented patients with idiopathic PD were enrolled in this study. Patients had been diagnosed with idiopathic PD according to the Queen Square Brain Bank criteria and gave informed consent met inclusion criteria. Dementia was excluded using specific diagnostic clinical criteria (Emre et al., 2007) . Demographic data, disease characteristics, and medication (with particular attention to dopamine agonists and psychoactive drugs) were collected during a face-to-face interview. Severity of motor symptoms was measured by the Unified Parkinson's Disease Rating Scale (UPDRS, section III) and the Hoehn and Yahr scale in the "on" state. The levodopa equivalent daily dose (LEDD) was calculated for dopamine agonists (DA-LEDD) and for the dopamine agonists + L-dopa (total LEDD). Patients were recruited from the University Department of Neurology in Montpellier.
Patients with Schizophrenia. Sixty-four patients with schizophrenia who fulfill the DSM-IV-TR diagnostic criteria for schizophrenia, currently receiving inpatient or outpatient care were included. Patients were in a stable phase of the illness according to the current treating psychiatrist with no hospitalizations or changes in housing in the month prior to entering the study. Severity of symptoms was rated by clinicians blind to the patient's task performance, with the Positive And Negative Syndrome Scale (PANSS; Kay, Fiszbein, & Opler, 1987) . Exclusion criteria were: (a) known neurological disease, (b) developmental disability, (c) substance abuse in the past 3 months, (d) current major depressive episode. Premorbid intellectual capacities were estimated with the French version of the National Adult Reading Test (f-NART; Mackinnon & Mulligan, 2005) . Participants were recruited from the University Department of Adult Psychiatry in Montpellier.
Hayling Sentence Completion
The HSCT was administered following the procedure described in the normative study of the French version of the test (f-HSCT) (Bayard et al., accepted) . It was systematically introduced into a battery of standardized neuropsychological tests used in routine clinical procedure.
Statistical Analyses
To establish the individual profile of each patient, f-HSCT results were compared to the appropriate norms developed by the authors. Clinical decision could be either "deficit" if the Z-score was inferior to −1.65, or "borderline" if the Z-score was between −1.64 and −1, or "average" if the Z-score was between −1 and 1, or "superior" if the Z-score was between 1 and 1.64 or "very superior" is the Z-score was superior to 1.65. A performance was considered as "deviant" if a deficit or a borderline score was observed (Strauss, Sherman, & Spreen, 2006) . Antiparkinsonian drugs with at least one DA was reported in 70% (DA-LEDD = 267 ± 127 mg ) and L-dopa in 88.5% (LEDD = 600 ± 250 mg ) of patients. The total LEDD was 687 ± 340 mg . Thirteen patients (15.3%) were taking antidepressants and 13 (15.3%) benzodiazepines.
Results
Demographic Data and Clinical Characteristics
Schizophrenia. The mean duration of illness was 9.76 ± 9.07 years [range = 1-35] and the mean age-at-onset was 24.95 ± 9.86 years [range = 13-57]. All patients were taking antipsychotic medication. Typical antipsychotic agents were taken by 34 patients and atypical antipsychotic agents were given to 30 patients in a standard dose (chlorpromazine equivalents = 800 mg/day; range = 125-3650). In addition, 16 patients were receiving benzodiazepines, nine antidepressants, and eight anticholinergics. Average level of positive and negative symptoms was respectively 15.35 ± 4.75 (range = 7-25) and 19.41 ± 6.83 (range = 7-38). Premorbide intellectual level (f-NART) globally felt within normal range with a mean score of 102 ± 8.18 . Table 1 presents the response time and number of errors in the f-HSCT for patients with PD and schizophrenia.
Hayling Sentence Completion Test
Error Score
As observed in the normative sample, errors on the automatic condition were rare in both clinical groups, with 90% of patients with PD (inter-quartile range = 1, range 0-2) and 89% of patients with schizophrenia (inter-quartile range = 1, range 0-2) making less than two errors on the total number of responses produced in this condition. No further analyses were performed on this raw score. As shown in Fig. 1A , 46% of patients with PD had a deviant performance for the inhibition error score, including 35% who were borderline and 11% who had a deficit. Sixty-one percent of patients with schizophrenia had a deviant result for the inhibition error score, including 25% considered as borderline and 36% with a deficit (Fig. 1B) . Note that 49% of patients with PD and 38% of patients with schizophrenia exhibited a normal performance on this f-HCST indice.
Time Latencies
Most patients with PD completed the automatic condition with average time latencies lower than 1 s (90%) or lower than 2 s (98%) (inter-quartile range = 0, range 0-2). All patients with schizophrenia completed this condition in less than 2 s (inter-quartile range = 0, range 0-1) and the majority in less than 1 s (80%). No further analyses were performed on this raw score.
With respect to the inhibition response time score, the proportion of patients with a deviant performance was similar in both clinical samples (25% and 23%). Fourteen percent of patients with PD were borderline and 11% had a deficit (Fig. 1A) whereas 9% of patients with schizophrenia had a borderline performance and 14% had a deficit (Fig. 1B) . Approximately two-thirds of patients with PD and schizophrenia had a normal performance for this indice, respectively 64% (Fig. 1A) and 67% (Fig. 1B) .
Finally, when both response time latencies and error scores were considered, 55% of patients with PD had a deviant performance (i.e., borderline or deficit) on at least one of the HSCT inhibition indices. This rate was 69% in patients with schizophrenia.
Clinical Correlates
In PD, we found that patients with a deviant performance on at least one of the f-HSCT inhibition indices had lower score on the MMSE compared to those with normal to superior performance, = − , p = .003, d = 0.67 (28.9 ± 1.23 vs. 27.91 ± 1.71, respectively).
Discussion
In this study, we were interested in exploring the clinical utility and the sensitivity of the f-HSCT in PD and schizophrenia. As in various psychiatric and neurological disorders, the assessment of executive functioning, including inhibition control, has a major interest in both schizophrenia (Reichenberg & Harvey, 2007) and PD (Kudlicka, Clare, & Hindle, 2011) . Nevertheless, the measure of executive performances, in particular the prepotent response inhibition may induce several methodological problems in these specific contexts . In fact, a major challenge in the assessment of executive functions is the "impurity" problem, namely that execution of the task known to measure executive functions might, in reality, be triggering non-executive processes unrelated to the task (e.g., processing speed, semantic processing, lexical activation, and visual scanning). By consequences, in order to establish the executive origin of a deficit of a specific patient, one must be able to identify or control practically all other non-executive contributions to the task.
Practically all inhibition tests, including the HSCT, imply the measurement of a time-based performance relying on various motor aspects, i.e., discrete finger response, graph motor skills and speech production . It has been clearly documented that PD patients' impairment in executive tasks involving processing speed could be a direct consequence of their cognitive slowing (Dujardin et al., 2007) . Similarly, it has been proposed that deficits in executive sub-processes may simply reflect more general cognitive decline in schizophrenia. In this respect, it has been shown that executive functioning impairments in schizophrenia are largely determined by other general cognitive factors and particularly by processing speed (Raffard & Bayard, 2012; Savla et al., 2012) . In both PD and schizophrenia, we found that patients' time latency performances on the f-HSCT automatic condition felt within the ranges of the normative sample. Same pattern of results was observed for the error indices. Performances on the automatic section can be used to examine speed of lexical activation which is the main non-executive process involved in this test. In view of our findings, in both PD and schizophrenia, this process does not seem to be considered as a potential non-executive contributor to the f-HSCT inhibition performance. It should be pointed out that, in our normative study, no norms were proposed for the automatic condition given the restricted ranges of response latencies and errors (Bayard et al., accepted) . Therefore, no ratio scores were derived from the automatic and inhibition conditions during the normalization process.
We observed that slightly more than half of patients with PD and more than two-thirds of patients with schizophrenia had a deviant performance on at least one of the f-HSCT inhibition indices after applying the norms. These clinical observations are in line with previous case-controlled studies using the HSCT performed on modest clinical samples of patients with PD (Obeso et al., 2011; Rochester et al., 2004; Uekermann et al., 2004) or with schizophrenia (Chan et al., 2012; Chan, Chen, Cheung, & Cheung, 2004; Chan et al., 2010; Groom et al., 2008; Joshua, Gogos, & Rossell, 2009; Martin et al., 2015) . Globally, all these studies indicated that both PD and schizophrenia patients were slower and had higher error rate on the inhibition condition than healthy controls. It should be noted that in the literature, performances on the automatic condition are never reported in PD and are not systematically described in schizophrenia. When results were available for this condition, no significant difference was observed between patients with schizophrenia and controls (Chan et al., 2012 (Chan et al., , 2004 (Chan et al., , 2010 or small effect sizes were noted (Groom et al., 2008; Joshua et al., 2009 ). This observation is in accordance with our results showing that performances on the automatic condition of patients with schizophrenia felt within the ranges of the normative sample.
In addition, our results emphasized the heterogeneity of the inhibition impairment in both PD and schizophrenia when individual profile analysis is considered. This observation extends previous evidences classically described in both diseases (Raffard & Bayard, 2012; Tremblay, Achim, Macoir, & Monetta, 2013) . We also corroborated the extensive literature that underpins, on the one hand, the significant contribution of the negative symptoms in executive control in schizophrenia (Bora & Pantelis, 2015; Bora, Yücel, & Pantelis, 2010) and, on the other hand, the global cognitive status involvement in this specific function in PD (Burdick et al., 2014) . From a clinical perspective, all of these observations stressed the strong clinical utility the f-HSCT as a qualifier of differential impairment and a potential marker for patient subtyping.
Our study has several limitations. First, our two sample sizes were relatively small. Therefore, the results should only be generalized with caution. Second, patients with schizophrenia who participated in the study were chronic patients and clinically stabilized. Therefore, our results cannot be generalized to persons experiencing acute phases of illness or their first episode schizophrenia. Third, we recruited non-demented patients with PD, and it should be pertinent in the future to explore the f-HSCT performances of patients with Parkinson's dementia.
In conclusion, the results of our study suggest that the f-HSCT has strong potential for characterizing prepotent response inhibition impairment in both PD and schizophrenia. In these diseases, it appears that the non-executive potential contributors triggered by the test do not have to be a priori considered for the inhibition impairment interpretation. However, attention should be drawn to the fact that results on the inhibition condition need to be carefully interpreted if impairment is observed on the automatic section indices. Especially as normative data distribution does not allow calculating a ratio between the automatic and the inhibition conditions.
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